Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$3.31
+1.8%
$2.94
$2.12
$5.80
$322.82M1.941.49 million shs1.08 million shs
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$0.73
-1.6%
$0.85
$0.66
$2.43
$86.15M0.882.69 million shs1.19 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.46
+0.7%
$6.40
$4.58
$9.78
$371.52M1.85516,471 shs514,915 shs
Prothena Corporation plc stock logo
PRTA
Prothena
$6.07
-0.2%
$6.66
$4.32
$25.42
$327.27M-0.07786,711 shs1.14 million shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+1.85%+0.61%+22.59%+15.73%+27.31%
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-1.59%+0.63%-5.74%-9.29%-57.73%
CryoPort, Inc. stock logo
CYRX
CryoPort
+0.67%+13.72%+23.10%+22.50%+7.96%
Prothena Corporation plc stock logo
PRTA
Prothena
-0.16%+0.17%+32.24%-48.30%-70.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.5256 of 5 stars
3.51.00.00.03.10.00.0
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
4.1572 of 5 stars
3.31.00.04.53.32.50.6
CryoPort, Inc. stock logo
CYRX
CryoPort
3.1686 of 5 stars
4.42.00.00.01.93.30.0
Prothena Corporation plc stock logo
PRTA
Prothena
3.1656 of 5 stars
4.22.00.00.01.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.14206.43% Upside
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
2.67
Moderate Buy$4.68540.41% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0047.45% Upside
Prothena Corporation plc stock logo
PRTA
Prothena
2.33
Hold$31.50418.95% Upside

Current Analyst Ratings Breakdown

Latest CHRS, CYRX, AQST, and PRTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/17/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
5/28/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underperform
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$6.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $14.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $18.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$57.56M5.71N/AN/A($0.66) per share-5.02
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$266.96M0.32$0.29 per share2.55($1.14) per share-0.64
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.64N/AN/A$7.44 per share1.00
Prothena Corporation plc stock logo
PRTA
Prothena
$135.16M2.42N/AN/A$9.05 per share0.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$44.14M-$0.59N/AN/AN/A-100.02%N/A-50.31%8/5/2025 (Estimated)
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$28.51M-$1.13N/AN/AN/A-66.30%N/A-26.51%8/6/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Prothena Corporation plc stock logo
PRTA
Prothena
-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)

Latest CHRS, CYRX, AQST, and PRTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
5/12/2025Q1 2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.31-$0.35-$0.04-$0.49$59.79 million$7.60 million
5/8/2025Q1 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
4.87
4.48
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/A
1.22
1.20
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Prothena Corporation plc stock logo
PRTA
Prothena
N/A
9.00
9.00

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
72.82%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Prothena Corporation plc stock logo
PRTA
Prothena
97.08%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
7.85%
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
8.08%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Prothena Corporation plc stock logo
PRTA
Prothena
9.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.33 million91.53 millionOptionable
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
330115.93 million106.57 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.07 millionOptionable
Prothena Corporation plc stock logo
PRTA
Prothena
13053.83 million48.88 millionOptionable

Recent News About These Companies

Prothena Announces Corporate Restructuring
PRTA Prothena Corporation plc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$3.31 +0.06 (+1.85%)
As of 06/30/2025 04:00 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Coherus Oncology stock logo

Coherus Oncology NASDAQ:CHRS

$0.73 -0.01 (-1.59%)
As of 06/30/2025 04:00 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.46 +0.05 (+0.67%)
As of 06/30/2025 04:00 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Prothena stock logo

Prothena NASDAQ:PRTA

$6.07 -0.01 (-0.16%)
As of 06/30/2025 04:00 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.